Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMDAE + Anti-inflammatory Agent for Ultra-resistant Schizophrenia
NCT05240976Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Feb 2022
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia (2 arms), sponsored by China Medical University Hospital. Primary endpoint: Change of cognitive function at Week 12. Started Feb 2022; status: recruiting.
02
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05240976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05240976.